Literature DB >> 26581522

Molecular mechanisms of activity and derepression of alternative lengthening of telomeres.

Hilda A Pickett1, Roger R Reddel2.   

Abstract

Alternative lengthening of telomeres (ALT) involves homology-directed telomere synthesis. This multistep process is facilitated by loss of the ATRX or DAXX chromatin-remodeling factors and by abnormalities of the telomere nucleoprotein architecture, including altered DNA sequence and decreased TRF2 saturation. Induction of telomere-specific DNA damage triggers homology-directed searches, and NuRD-ZNF827 protein-protein interactions provide a platform for the telomeric recruitment of homologous recombination (HR) proteins. Telomere lengthening proceeds by strand exchange and template-driven DNA synthesis, which culminates in dissolution of HR intermediates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581522     DOI: 10.1038/nsmb.3106

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  81 in total

Review 1.  Break-induced replication and recombinational telomere elongation in yeast.

Authors:  Michael J McEachern; James E Haber
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

2.  Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions.

Authors:  Anthony J Cesare; Zeenia Kaul; Scott B Cohen; Christine E Napier; Hilda A Pickett; Axel A Neumann; Roger R Reddel
Journal:  Nat Struct Mol Biol       Date:  2009-11-22       Impact factor: 15.369

Review 3.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

4.  Purification of proteins associated with specific genomic Loci.

Authors:  Jérôme Déjardin; Robert E Kingston
Journal:  Cell       Date:  2009-01-09       Impact factor: 41.582

5.  DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA.

Authors:  Clare L Fasching; Axel A Neumann; Alessandra Muntoni; Thomas R Yeager; Roger R Reddel
Journal:  Cancer Res       Date:  2007-07-24       Impact factor: 12.701

6.  Mechanisms underlying telomere repeat turnover, revealed by hypervariable variant repeat distribution patterns in the human Xp/Yp telomere.

Authors:  D M Baird; A J Jeffreys; N J Royle
Journal:  EMBO J       Date:  1995-11-01       Impact factor: 11.598

7.  Organismal propagation in the absence of a functional telomerase pathway in Caenorhabditis elegans.

Authors:  Daniel H Lackner; Marcela Raices; Hugo Maruyama; Candy Haggblom; Jan Karlseder
Journal:  EMBO J       Date:  2012-03-16       Impact factor: 11.598

8.  Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.

Authors:  Kylie Bower; Christine E Napier; Sara L Cole; Rebecca A Dagg; Loretta M S Lau; Emma L Duncan; Elsa L Moy; Roger R Reddel
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

9.  Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes.

Authors:  Michael Lee; Mark Hills; Dimitri Conomos; Michael D Stutz; Rebecca A Dagg; Loretta M S Lau; Roger R Reddel; Hilda A Pickett
Journal:  Nucleic Acids Res       Date:  2013-11-12       Impact factor: 16.971

10.  MUS81-EME2 promotes replication fork restart.

Authors:  Alessandra Pepe; Stephen C West
Journal:  Cell Rep       Date:  2014-05-09       Impact factor: 9.423

View more
  81 in total

1.  DNA repair: Telomere-lengthening mechanism revealed.

Authors:  Caitlin M Roake; Steven E Artandi
Journal:  Nature       Date:  2016-10-19       Impact factor: 49.962

Review 2.  Bloom's syndrome: Why not premature aging?: A comparison of the BLM and WRN helicases.

Authors:  Christelle de Renty; Nathan A Ellis
Journal:  Ageing Res Rev       Date:  2016-05-26       Impact factor: 10.895

Review 3.  Telomeres in cancer: tumour suppression and genome instability.

Authors:  John Maciejowski; Titia de Lange
Journal:  Nat Rev Mol Cell Biol       Date:  2017-01-18       Impact factor: 94.444

4.  Specific death of ALT cells through TSPYL5 depletion.

Authors:  Eloïse Claude; Harikleia Episkopou; Anabelle Decottignies
Journal:  Mol Cell Oncol       Date:  2019-09-11

5.  RPA Stabilization of Single-Stranded DNA Is Critical for Break-Induced Replication.

Authors:  Patrick Ruff; Roberto A Donnianni; Eleanor Glancy; Julyun Oh; Lorraine S Symington
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

Review 6.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

7.  Hepatocyte Growth Factor Improves the Therapeutic Efficacy of Human Bone Marrow Mesenchymal Stem Cells via RAD51.

Authors:  Eun Ju Lee; Injoo Hwang; Ji Yeon Lee; Jong Nam Park; Keun Cheon Kim; Gi-Hwan Kim; Chang-Mo Kang; Irene Kim; Seo-Yeon Lee; Hyo-Soo Kim
Journal:  Mol Ther       Date:  2017-12-19       Impact factor: 11.454

8.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

Review 9.  Telomere recombination pathways: tales of several unhappy marriages.

Authors:  Neal F Lue; Eun Young Yu
Journal:  Curr Genet       Date:  2016-09-25       Impact factor: 3.886

Review 10.  Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.

Authors:  Li Teng Khoo; Liuh-Yow Chen
Journal:  EMBO Rep       Date:  2018-11-16       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.